Morgan & Morgan is pleased to announce that attorney Michael Goetz will speak at a Pradaxa litigation webinar to address the legal implications of the potentially lethal side effects of the popular blood thinner drug. Mr. Goetz will present updates on the latest developments in Pradaxa litigation and effective strategies for case selection. Pradaxa (dabigatran) is an oral blood thinner in class of drugs called direct thrombin inhibitors, prescribed to prevent strokes among patients with non-valvular atrial fibrillation (an irregular heartbeat).
The U.S. Food and Drug Administration (FDA) has agreed to review mounting post-market reports of bleeding complications, but have yet to release any new warnings on the drug. The growing recent deaths of patients using Pradaxa have illustrated the disturbing possible effects of the drug’s use. Recently, three doctors at the University of Utah reported in the Journal of Neurosurgery that an 83-year-old man was admitted after a routine fall in his home, but experienced extensive brain hemorrhaging that could not be stopped due to the presence of the drug in his blood.
The FDA is still reviewing the risks Pradaxa, but there may be significant potentially-fatal bleeding events that are caused or made worse by the popular blood thinner prescription drug. If you or a loved one has suffered a bleeding complication while taking Pradaxa, you may be entitled to seek compensation through a Pradaxa lawsuit. As shown by this upcoming speaking engagement for attorney Michael Goetz, Morgan and Morgan is uniquely tailored to seek justice in Pradaxa cases. Contact an experienced Pradaxa attorney to see if you may be eligible to see compensation for medical bills, lost wages, and pain and suffering.
comments